CYTR - CytRx Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7001
+0.0100 (+1.45%)
As of 1:32PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.7000
Open0.7100
Bid0.6950 x 1000
Ask0.7100 x 1200
Day's Range0.6901 - 0.7300
52 Week Range0.3300 - 2.1000
Volume103,921
Avg. Volume164,823
Market Cap23.55M
Beta (3Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-0.5030
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
    PR Newswire6 days ago

    CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

    LOS ANGELES, March 12, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology treatment and diagnostics, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for its Albumin Companion Diagnostic (ACDx). The article, titled "Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors," has been published online in Nuclear Medicine and Molecular Imaging.  The abstract may be found and the full article purchased online at https://doi.org/10.1007/s13139-019-00587-w.

  • CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
    PR Newswirelast month

    CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor

    LOS ANGELES, Feb. 13, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for LADR-7 (AE-Keto-Sulf07), one of its lead LADR™ (Linker Activated Drug Release) candidates.  The article, entitled "Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound" to be published in the Journal of Controlled Release, a leading journal for drug delivery on February 28, 2019.  The abstract may be found and full article purchased online at  https://www.sciencedirect.com/journal/journal-of-controlled-release/vol/296.

  • CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
    PR Newswirelast month

    CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy

    LOS ANGELES, Feb. 11, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted comments from an OncLive® article dated February 1, 2019 that an estimated majority of oncology patients do not have targetable genetic mutations that would make them eligible for targeted treatment.

  • CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
    PR Newswirelast month

    CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S

    LOS ANGELES, Feb. 6, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, highlighted positive Phase 2/3 clinical trial data from arimoclomol licensee Orphazyme A/S (ORPHA.CO). Orphazyme is currently developing arimoclomol in four different indications, including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM).

  • CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
    PR Newswire2 months ago

    CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial

    LOS ANGELES, Jan. 14, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with relapsed or refractory colorectal cancer (CRC) who have been previously treated with standard of care (SOC) therapy.  This is the fourth trial conducted by NantCell which will investigate high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in certain high unmet need cancer indications.

  • CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
    PR Newswire3 months ago

    CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic

    LOS ANGELES, Dec. 21, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the Company) has concluded the pre-clinical phase of its development for its albumin binding ultra high potency LADR™ (Linker Activated Drug Release) drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10, and for its unique albumin companion diagnostic (ACDx).  As a result of completing this work, operations taking place at the pre-clinical laboratory located in Freiburg, Germany will no longer be needed. The LADR™ platform combines Centurion's proprietary linker chemistry with albumin biology to create anti-cancer molecules that the Company believes will deliver highly potent agents directly to the tumor, while avoiding unacceptable systemic toxicity.  The pre-clinical laboratory synthesized and evaluated over 75 rationally-designed drug conjugates across two distinct classes of compounds, the auristatins and maytansinoids.

  • CytRx Corporation to Present at the 11th Annual LD Micro Main Event
    PR Newswire4 months ago

    CytRx Corporation to Present at the 11th Annual LD Micro Main Event

    CytRx's wholly owned subsidiary, Centurion BioPharma Corporation, is focused on the development of personalized medicine that will transform solid tumor treatment. This transformational strategy combines a portfolio of novel, anti-cancer drug candidates that employ LADR™ (Linker Activated Drug Release) technology, a discovery engine designed to leverage Centurion's expertise in albumin biology and linker technology for the development of a new class of breakthrough anti-cancer therapies with a unique albumin companion diagnostic (ACDx) that can help identify patients who are most likely to benefit from treatment with the LADR™-derived therapies. This technology allows for the delivery of higher doses of drug directly to the tumor, while avoiding much of the off-target toxicity observed with the parent molecules.  Centurion BioPharma Corporation's website is www.centurionbiopharma.com.

  • GlobeNewswire4 months ago

    Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.) — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT

    Q3 2018 CytRx Corp Earnings Call

  • Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
    Zacks4 months ago

    Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems

    Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems

  • Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
    Zacks4 months ago

    Bet on Rising P/E Investing With These 5 Top-Ranked Stocks

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
    PR Newswire4 months ago

    CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

    Aldoxorubicin Is Part of the NANT Cancer Vaccine Combinations Which Include Immunotherapy and Cell-based Therapy Early Safely Data Are Encouraging and There Are Emerging Positive Signals of Clinical Activity ...

  • Associated Press4 months ago

    CytRx: 3Q Earnings Snapshot

    On a per-share basis, the Los Angeles-based company said it had a loss of 10 cents. The cancer drug developer posted revenue of $250,000 in the period. The company's shares closed at 75 cents. A year ago, ...

  • CytRx Corporation Reports Third Quarter 2018 Financial Results
    PR Newswire4 months ago

    CytRx Corporation Reports Third Quarter 2018 Financial Results

    Quarter Marked by Centurion's Filing of a Provisional Patent for Breakthrough Personalized Medicine Companion Diagnostic to Accompany LADR Assets Improved Finances and Capital Structure Through Expiration ...

  • Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
    PR Newswire5 months ago

    Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline

    LOS ANGELES, Oct. 31, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that key emerging cancer treatment trends by Big Pharma, including combining immunotherapy with effective chemotherapy regimens, are resulting in significant advancements for the treatment of patients with high unmet medical need types of cancer.  CytRx, along with its wholly owned subsidiary Centurion Biopharma, believe these trends strengthen and enhance the value proposition for their rationally designed albumin binding ultra-high potency anti-cancer agents.

  • CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
    PR Newswire5 months ago

    CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018

    LOS ANGELES , Oct. 29, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial ...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of CYTR earnings conference call or presentation 6-Aug-18 3:00pm GMT

    Q2 2018 CytRx Corp Earnings Call

  • CytRx Corporation to Present at the 2018 MicroCap Conference
    PR Newswire6 months ago

    CytRx Corporation to Present at the 2018 MicroCap Conference

    LOS ANGELES, Sept. 25, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, President and Chief Operating Officer, will present at the 2018 MicroCap Conference on Tuesday, October 2, 2018 at 3:00 P.M. Eastern Daylight Time at the Essex House in New York City. The MicroCap Conference is an exclusive event dedicated to connecting small and micro-cap companies with high-level, institutional and retail investors. The MicroCap Conference will highlight the most attractive companies across various sectors.

  • CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
    PR Newswire6 months ago

    CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S

    LOS ANGELES, Sept. 13, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received a milestone payment of $250,000 (USD) from Orphazyme A/S (ORPHA.CO). The payment is a result of Orphazyme dosing the first patient in their Phase 3 clinical trial evaluating arimoclomol in patients with amyotrophic lateral sclerosis (ALS).

  • CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
    PR Newswire7 months ago

    CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018

    LOS ANGELES, Aug. 27, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, President and Chief Operating Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference. H.C. Wainwright & Co. LLC is an investment bank dedicated to providing corporate finance, strategic advisory, research, sales and trading, and other related services to public and private growth companies across multiple sectors and regions. At the Conference, more than 250 presenting companies and credentialed investors consisting of portfolio managers, hedge fund managers, and family offices will have the opportunity to engage in one-on-one meetings and networking opportunities.

  • ACCESSWIRE7 months ago

    CytRx Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / CytRx Corporation (NASDAQ: CYTR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 11:00 AM Eastern Time. ...

  • Associated Press7 months ago

    CytRx: 2Q Earnings Snapshot

    The Los Angeles-based company said it had a loss of 10 cents per share. The company's shares closed at $1.15. A year ago, they were trading at $3.78. _____ This story was generated by Automated Insights ...

  • CytRx Corporation Reports Second Quarter 2018 Financial Results
    PR Newswire7 months ago

    CytRx Corporation Reports Second Quarter 2018 Financial Results

    Substantial Reduction in CytRx Cash Burn Rate This Quarter Company to Host Conference Call Today at 11:00 am ET (8:00 am PT) LOS ANGELES , Aug. 6, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), ...

  • PR Newswire8 months ago

    CytRx Corporation Pays Off Balance of Outstanding Debt

    LOS ANGELES, Aug. 1, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has made the final scheduled payment under a long-term loan facility agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P.  As of, August 1, 2018, the Hercules loan was paid in full. "Our current focus is on securing strategic partnerships for our wholly owned subsidiary Centurion BioPharma Corporation.

  • PR Newswire8 months ago

    CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018

    LOS ANGELES, July 30, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the quarter ended June 30, 2018 on Monday, August 6, 2018. CytRx executives Eric L. Curtis, President and Chief Operating Officer, and John Caloz, Chief Financial Officer, will hold a conference call and webcast beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on that day to discuss the financial results as well as provide an overview of corporate achievements of both CytRx Corporation and Centurion BioPharma Corporation. To access the conference call, dial (+1)844-358-6753 (U.S. and Canada) or (+1)216-562-0397 (international callers) and enter the conference ID number: 5991089.  A live and archived webcast will be available in the News and Events/Events Calendar section of the company's website, www.cytrx.com.